Trial reportBMC nephrology2010
Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
Trial report in BMC nephrology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Biocompatible dialysis fluids for peritoneal dialysis.The Cochrane database of systematic reviews · 2018Pooled it
- Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisPooled it
- Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients.BMC nephrology · 2014Trial
- The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2012Trial
- Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.Journal of the American Society of Nephrology : JASN · 2012Trial
- Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- Article
- microRNA regulation of peritoneal cavity homeostasis in peritoneal dialysis.BioMed research international · 2015Review
- An update on peritoneal dialysis solutions.Nature reviews. Nephrology · 2012Review
- Baseline serum interleukin-6 predicts cardiovascular events in incident peritoneal dialysis patients.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisArticle
- Higher Dialysate Matrix Metalloproteinase-2 Levels Are Associated with Peritoneal Membrane Dysfunction.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisArticle
- Trials (and tribulations) of biocompatible peritoneal dialysis fluids.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe main hypothesis of this study is that neutral pH, low glucose degradation product (GDP) peritoneal dialysis (PD) fluid better preserves residual renal function in PD patients over time compared with conventional dialysate. METHODS/
designInclusion criteria are adult PD patients (CAPD or APD) aged 18-81 years whose first dialysis was within 90 days prior to or following enrolment and who have a residual GFR ≥ 5 ml/min/1.73 m2, a urine output ≥ 400 ml/day and an ability to understand the nature and requirements of this trial. Pregnant or lactating patients or individuals with an active infection at the time of enrolment, a contra-indication to PD or participation in any other clinical trial where an intervention is designed to moderate rate of change of residual renal function are excluded. Patients will be randomized 1:1 to receive either neutral pH, low GDP dialysis solution (Balance) or conventional dialysis solution (Stay.safe) for a period of 2 years. During this 2 year study period, urinary urea and clearance measurements will be performed at 0, 3, 6, 9, 12, 18 and 24 months. The primary outcome measure will be the slope of residual renal function decline, adjusted for centre and presence of diabetic nephropathy. Secondary outcome measures will include time from initiation of peritoneal dialysis to anuria, peritoneal small solute clearance, peritoneal transport status, peritoneal ultrafiltration, technique survival, patient survival, peritonitis rates and adverse events. A total of 185 patients has been recruited into the trial. DISCUSSION: This investigator-initiated study has been designed to provide evidence to help nephrologists determine the optimal dialysis solution for preserving residual renal function in PD patients.
trial registrationAustralian New Zealand Clinical Trials Registry Number: ACTRN12606000044527.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.